Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2019-04-11 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Meddelande om stabiliseringsåtgärder
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated April 11, 2019, titled "Meddelande om stabiliseringsåtgärder" (Announcement of stabilization measures). It explicitly discusses stabilization transactions performed by Erik Penser Bank AB in relation to the offering and listing of Ascelia Pharma AB's shares on Nasdaq Stockholm, referencing EU Market Abuse Regulation (MAR) Article 5(4). This type of announcement, detailing actions taken during or immediately following a capital raising/listing event, specifically relates to financing activities and capital structure changes. While it is a press release, its core subject matter aligns best with 'Capital/Financing Update' (CAP) rather than a general 'Regulatory Filing' (RNS) or 'Report Publication Announcement' (RPA), as it reports on the execution of terms related to a recent offering/listing.
2019-04-11 Swedish
Stabilisation notice
Regulatory Filings Classification · 95% confidence The document is titled "PRESS RELEASE" and specifically discusses a "Stabilisation notice" related to the recent offering and listing of Ascelia Pharma AB's shares on Nasdaq Stockholm. It details stabilization transactions carried out by the stabilization manager (Erik Penser Bank AB) in accordance with the Market Abuse Regulation (MAR). This type of announcement, concerning market stabilization activities following an offering or listing, is a specific regulatory disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Investor Presentation (IP). Since it is a specific regulatory notice about market activity following a capital event, and it doesn't fit perfectly into the other specific categories like Director's Dealing (DIRS) or Major Shareholding (MRQ), it falls best under the general regulatory announcement category, RNS, as it is a mandatory disclosure under EU regulations (MAR) that doesn't have a more specific code provided (like a prospectus supplement or offering circular). However, given the context of capital markets activity (stabilization post-offering), it is a specific type of corporate action disclosure. Since 'CAP' is for financing updates and 'SHA' is for share issues, and this relates to post-offering market support, RNS is the most appropriate fallback for a specific regulatory notice that isn't a core financial report or management change.
2019-04-11 English
Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology
Earnings Release Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces the publication of encouraging results from a Phase I clinical study in a peer-reviewed medical journal ("Cancer Chemotherapy and Pharmacology"). It details clinical trial information (NCT03295084), study aims, patient numbers, and quotes from the Chief Medical Officer. This type of announcement, focusing on clinical trial updates and scientific publication, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of results rather than a comprehensive financial report (10-K or IR), and it is not a transcript (CT) or a formal investor presentation (IP), it fits best as an Earnings Release (ER) which often includes operational/clinical milestones, or RNS as a general regulatory announcement. Given the focus on clinical data publication, ER is a strong candidate, but RNS is the most appropriate fallback for non-standard operational announcements. However, many companies use ER to announce significant clinical milestones alongside or instead of quarterly financials. Since this is a press release announcing specific study results and publication, and it is not a formal financial report, I will classify it as an Earnings Release (ER) as it pertains to operational performance milestones, or RNS. Given the context of financial reporting databases, press releases announcing clinical trial results are often categorized under ER if they are timely, or RNS if they are purely operational/regulatory. Since it is a press release announcing a key operational/clinical milestone, ER is often used for such announcements, but RNS is the safest catch-all for non-standard announcements. I will lean towards RNS as it is a general regulatory announcement about a study publication, which doesn't fit the core definitions of ER (which usually implies quarterly financial highlights). FY 2019
2019-04-08 English
Lovande fas-1 resultat när Oncoral kombineras med det orala läkemedlet capecitabin. Resultaten publiceras i tidskriften Cancer Chemotherapy and Pharmacology
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the publication of Phase 1 study results for the drug Oncoral in the journal *Cancer Chemotherapy and Pharmacology*. It details clinical trial outcomes, tolerability, and future plans. This format—a formal announcement of clinical/scientific findings, often released via a press wire and referencing a published paper—is characteristic of an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category. Since it is a specific announcement about clinical trial results and publication, and not a comprehensive financial report (10-K, IR) or a management discussion (MDA), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company uses these announcements as their primary means of disseminating material news. Given the content is purely scientific/clinical news and not financial performance highlights, RNS is the most appropriate general regulatory category for material, non-financial news releases, although ER is sometimes used broadly for company updates. However, since the text explicitly states the information is being made public under the EU Market Abuse Regulation (MAR) and is a press release about clinical data, RNS (Regulatory Filings) serves as the best fit for a material, non-standard announcement.
2019-04-08 Swedish
Stabilisation notice
Report Publication Announcement Classification · 99% confidence The document is titled 'PRESS RELEASE' and specifically a 'Stabilisation notice' dated April 1, 2019, concerning transactions undertaken by Erik Penser Bank AB related to Ascelia Pharma AB's shares following an offering and listing on Nasdaq Stockholm. This notice details stabilization transactions carried out under the Market Abuse Regulation (MAR) and includes specific transaction tables (Date, Quantity, Price). This type of announcement, relating to market stabilization activities following an offering, is a specific type of regulatory disclosure. It is not a full annual report (10-K), an earnings release (ER), or a general investor presentation (IP). Since it is a specific regulatory disclosure concerning market activity related to a recent offering, it fits best under the general 'Regulatory Filings' category (RNS) as it is a mandatory disclosure under EU regulations (MAR) that doesn't fit the more specific categories like DIRS (Director's Dealing) or DIV (Dividend Notice). Given the context of market stabilization following an offering, RNS is the most appropriate general regulatory filing code.
2019-04-01 English
Meddelande om stabiliseringsåtgärder
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated April 1, 2019, titled "Meddelande om stabiliseringsåtgärder" (Announcement of stabilization measures). It explicitly details stabilization transactions performed by Erik Penser Bank AB concerning Ascelia Pharma AB's shares following an offering and listing on Nasdaq Stockholm. This type of announcement, which reports on actions taken related to a recent capital market transaction (like an IPO or share offering stabilization), often falls under Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Since it specifically concerns actions taken post-offering to support the share price, it is most closely related to financing activities. However, given the specific nature of reporting on stabilization measures under MAR (Market Abuse Regulation), and the fact that it is an announcement about a specific market action rather than a comprehensive report or a general earnings release, it fits best under Capital/Financing Update (CAP) as it directly relates to the capital structure/offering mechanics, or potentially RNS if CAP is too broad. Looking at the definitions, CAP covers 'Updates on company fundraising, financing activities, or capital structure changes.' Stabilization is a direct activity related to the financing/offering. It is not a standard 10-K, ER, or IR. It is a specific regulatory disclosure related to the offering process. I will classify it as CAP due to the direct link to the share offering mechanics, although RNS is a close secondary option if CAP is reserved for primary fundraising events.
2019-04-01 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.